DERBY,
U.K. - February 19, 2019 - STERIS plc (NYSE: STE) ("STERIS"
or the "Company") announced that it will participate in the Raymond
James Institutional Investor Conference on Monday, March 4,
2019. Michael J. Tokich, STERIS's Senior Vice President
and Chief Financial Officer will present at 8:40 a.m. Eastern
Time.
A simultaneous webcast and replay of the Company's presentation
will be available on STERIS's investor relations website at
www.steris-ir.com. |
About STERIS
STERIS's mission is to help our Customers create a
healthier and safer world by providing innovative healthcare and
life science product and service solutions around the globe. For
more information, visit www.steris.com.
Investor Contact:
Julie Winter, Senior Director, Investor Relations
and Corporate Communications
Julie_Winter@steris.com
440 392 7245
Media Contact:
Stephen Norton, Senior Director, Corporate
Communications
Stephen_Norton@steris.com
440 392 7482
Forward-Looking
Statements
The conference presentation may contain statements
concerning certain trends, expectations, forecasts, estimates, or
other forward-looking information affecting or relating to STERIS
or its industry, products or activities that are intended to
qualify for the protections afforded "forward-looking statements"
under the Private Securities Litigation Reform Act of 1995 and
other laws and regulations. Forward-looking statements speak only
as to the date the statement is made and may be identified by the
use of forward-looking terms such as "may," "will," "expects,"
"believes," "anticipates," "plans," "estimates," "projects,"
"targets," "forecasts," "outlook," "impact," "potential,"
"confidence," "improve," "optimistic," "deliver," "orders,"
"backlog," "comfortable," "trend", and "seeks," or the negative of
such terms or other variations on such terms or comparable
terminology. Many important factors could cause actual results to
differ materially from those in the forward-looking statements
including, without limitation, disruption of production or
supplies, changes in market conditions, political events, pending
or future claims or litigation, competitive factors, technology
advances, actions of regulatory agencies, and changes in laws,
government regulations, labeling or product approvals or the
application or interpretation thereof. Other risk factors are
described in STERIS's securities filings, including Item 1A of
STERIS's Annual Report on Form 10-K for the year ended
March 31, 2018. Many of these important factors are outside of
STERIS's control. No assurances can be provided as to any result or
the timing of any outcome regarding matters described in STERIS's
securities filings or otherwise with respect to any regulatory
action, administrative proceedings, government investigations,
litigation, warning letters, cost reductions, business strategies,
earnings or revenue trends or future financial results. References
to products are summaries only and should not be considered the
specific terms of the product clearance or literature. Unless
legally required, STERIS does not undertake to update or revise any
forward-looking statements even if events make clear that any
projected results, express or implied, will not be realized. Other
potential risks and uncertainties that could cause actual results
to differ materially from those in the forward-looking statements
include, without limitation, (a) the receipt of approval of
STERIS's shareholders of the redomiciliation transaction, (b) any
regulatory or court approvals required for the redomiciliation
transaction not being obtained on the terms expected or on the
anticipated schedule, (c) the parties' ability to meet expectations
regarding the timing, completion and accounting and tax treatments
of the redomiciliation transaction, (d) operating costs, Customer
loss and business disruption (including, without limitation,
difficulties in maintaining relationships with employees,
Customers, clients or suppliers) being greater than expected
following the redomiciliation transaction, (e) STERIS's ability to
meet expectations regarding the accounting and tax treatment of the
Tax Cuts and Jobs Act ("TCJA") or the possibility that anticipated
benefits resulting from the TCJA will be less than estimated,
(f) changes in tax laws or interpretations that could increase
our consolidated tax liabilities, including, if the redomiciliation
transaction is consummated, changes in tax laws that would result
in STERIS Ireland being treated as a domestic corporation for
United States federal tax purposes, (g) the potential for
increased pressure on pricing or costs that leads to erosion of
profit margins, (h) the possibility that market demand will
not develop for new technologies, products or applications or
services, or business initiatives will take longer, cost more or
produce lower benefits than anticipated, (i) the possibility
that application of or compliance with laws, court rulings,
certifications, regulations, regulatory actions, including without
limitation those relating to FDA warning notices or letters,
government investigations, the outcome of any pending FDA requests,
inspections or submissions, or other requirements or standards may
delay, limit or prevent new product introductions, affect the
production and marketing of existing products or services or
otherwise affect STERIS's performance, results, prospects or value,
(j) the potential of international unrest, economic downturn
or effects of currencies, tax assessments, tariffs and/or other
trade barriers, adjustments or anticipated rates, raw material
costs or availability, benefit or retirement plan costs, or other
regulatory compliance costs, (k) the possibility of reduced
demand, or reductions in the rate of growth in demand, for STERIS's
products and services, (l) the possibility of delays in
receipt of orders, order cancellations, or delays in the
manufacture or shipment of ordered products or in the provision of
services, (m) the possibility that anticipated growth, cost
savings, new product acceptance, performance or approvals, or other
results may not be achieved, or that transition, labor,
competition, timing, execution, regulatory, governmental, or other
issues or risks associated with STERIS's businesses, industry or
initiatives including, without limitation, those matters described
in STERIS's 10-K for the year ended March 31, 2018 and other
securities filings, may adversely impact STERIS's performance,
results, prospects or value, (n) the impact on STERIS and its
operations, or tax liabilities, of Brexit or the exit of other
member countries from the EU, and the Company's ability to respond
to such impacts, (o) the impact on STERIS and its operations
of any legislation, regulations or orders, including but not
limited to any new trade or tax legislation, regulations or orders,
that may be implemented by the U.S. administration or Congress, or
of any responses thereto, (p) the possibility that anticipated
financial results or benefits of recent acquisitions, or of
STERIS's restructuring efforts, or of recent divestitures, or of
the targeted restructuring plan will not be realized or will be
other than anticipated, and (q) the effects of contractions in
credit availability, as well as the ability of STERIS's Customers
and suppliers to adequately access the credit markets when
needed.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Steris Corporation via Globenewswire
STERIS (NYSE:STE)
Historical Stock Chart
From Aug 2024 to Sep 2024
STERIS (NYSE:STE)
Historical Stock Chart
From Sep 2023 to Sep 2024